R. Sundaram

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Ranjini K Sundaram, R. K. Sundaram, Ranjini Sundaram, R Sundaram, Ranjini K. Sundaram
Publication record
99 papers · 2,521 citations · H-index 24

PAPERS

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes
20260 citationsauthor #8
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy
20252 citationsauthor #2
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
20250 citationsauthor #4
Abstract 2902: Systematic mapping of chemo-genomic interactions between DNA damaging agents and DNA damage repair genes with targeted CRISPR knockout screening
20250 citationsauthor #7
MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy
20250 citationsauthor #3
Abstract 6415: NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition
20250 citationsauthor #9
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition
20251 citationsauthor #9
712 Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma
20240 citationsauthor #2
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion
20244 citationsauthor #14
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
20244 citationsauthor #7
Abstract 7117: Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
20240 citationsauthor #3
O6-Guanine Targeting Novel DNA Cross-Linker and ATR Inhibitor Combination for MGMT-Silenced IDH1/2 Mutant Acute Myeloid Leukemia
20240 citationsauthor #2
Abstract 2866: NAPRTsilencing in rhabdomyosarcoma confers therapeutic vulnerabilities to NAD+depletion
20240 citationsauthor #5
Abstract 7123: Biomarker-targeted alkylator and DNA damage repair inhibitor combination for refractory and relapsed acute myeloid leukemia (AML)
20240 citationsauthor #2
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
20246 citationsauthor #7
Abstract A081 Biomarker-driven targeting of NAD metabolism in rhabdomyosarcoma
20240 citationsauthor #6
Abstract 3086: NAPRT silencing in oncometabolite-producing cancers confers therapeutic vulnerabilities to NAD+ depletion
20240 citationsauthor #11
Title. Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
20230 citationsauthor #7
MODL-02. DEVELOPMENT OF RODENT GLIOBLASTOMA MODELS OF MGMT-MEDIATED TEMOZOLOMIDE RESISTANCE
20231 citationsauthor #3
Abstract 1132: Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types
20230 citationsauthor #3
Abstract 1568: Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-/MMR- gliomas and glioblastoma
20231 citationsauthor #6
866 Preclinical Study of Pamiparib, a CNS Penetrant PARP Inhibitor, in IDH1/2 Mutated Gliomas
20230 citationsauthor #2
PARG inhibition induces nuclear aggregation of PARylated PARP1
20234 citationsauthor #5
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy
20229 citationsauthor #6
Mechanism-based design of agents that selectively target drug-resistant glioma
202280 citationsauthor #3
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
202217 citationsauthor #3
Abstract 294: Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
20220 citationsauthor #3
In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2
202219 citationsauthor #10
TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor.
202226 citationsauthor #11
Abstract P055: Targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitor and low-dose alkylating chemotherapy
20210 citationsauthor #5
CBIO-28. IDENTIFYING THE ROLE OF MISMATCH REPAIR IN TEMOZOLOMIDE-INDUCED ATR ACTIVATION FOR MGMT-METHYLATED GLIOBLASTOMA MULTIFORME
20210 citationsauthor #3
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity
202126 citationsauthor #10
EXTH-60. PRECLINICAL STUDY OF PAMIPARIB, A CNS-PENETRANT PARP INHIBITOR, IN IDH1/2 MUTATED GLIOMAS
20210 citationsauthor #2
Abstract 1179: MSH2 is necessary for temozolomide-induced ATR activation in MGMT-methylated cancers
20210 citationsauthor #4
Abstract P258: CBX-12 (alphalexTM-exatecan) sensitizes tumors to immune checkpoint blockade in an antigen agnostic manner by immune activation
20211 citationsauthor #5
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
202141 citationsauthor #3
Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore
20213 citationsauthor #7
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
202125 citationsauthor #3
Abstract P059: Exploiting mutant PPM1D-induced metabolic defects with nanoparticle-encapsulated NAMPT inhibitors
20210 citationsauthor #3
Correction to ‘Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity’
20211 citationsauthor #10
CRISPR screening identifies novel PARP inhibitor classification based on
20211 citationsauthor #4
Nanoparticle-Encapsulated NAMPT Inhibitors Administered via Convection Enhanced Delivery as a Novel Glioma Radiosensitization Strategy
20200 citationsauthor #3
Abstract 1059: Targeting IDH1/2 mutant cancers with unique combinations of DNA repair inhibitors
20200 citationsauthor #2
CBIO-14. ELUCIDATING THE MECHANISM OF TEMOZOLOMIDE-INDUCED ATR ACTIVATION IN MGMT-METHYLATED GLIOBLASTOMA MULTIFORME
20200 citationsauthor #3
Targeted DNA Damage Repair CRISPR/Cas9 Knockout Screen Identifies Novel Classification of Poly-ADP Ribose Polymerase Inhibitors Based on Key Base Excision Repair Proteins
20201 citationsauthor #4
Abstract 1389: Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib
20202 citationsauthor #4
Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.
20192 citationsauthor #2
MGMT-Deficiency Is a Biomarker to Guide Treatment of Solid Tumors with Temozolomide and ATR Inhibitors
20191 citationsauthor #4
PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
20195 citationsauthor #9
Temozolomide-Resistant Glioma Cells Are Sensitive to Chloroethylating Nitrosourea Compounds in Combination with ATR Inhibitors
20190 citationsauthor #3
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
201966 citationsauthor #2
Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors.
201953 citationsauthor #3
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
201871 citationsauthor #2
OC-0377: Targeting a Novel Function for SAMHD1 in DNA Repair for Radiation Therapy and PARP Inhibition
20180 citationsauthor #17
PDTM-22. TARGETING A NOVEL METABOLIC DEFECT IN PPM1D-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMAS
20180 citationsauthor #2
Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects
2018148 citationsauthor #2
Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors.
201856 citationsauthor #8
RDNA-05. SYNTHETIC SENSITIZATION OF MGMT-DEFICIENT TUMOR CELLS TO TEMOZOLOMIDE USING ATR INHIBITORS
20181 citationsauthor #3
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
2017475 citationsauthor #8
Abstract LB-290: Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors
20170 citationsauthor #8
Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas
201724 citationsauthor #7
DIPG-33. BIOLOGICAL CHARACTERIZATION OF PPM1D MUTATIONS IN THE CONTEXT OF DIPG
20170 citationsauthor #2
Abstract B25: “TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair targeted drug discovery
20170 citationsauthor #7
SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination.
2017170 citationsauthor #19
Production of 2-Hydroxyglutarate by IDH Mutant Malignancies Induces a BRCAness State That Can be Exploited By PARP Inhibitors and Radiation
20170 citationsauthor #10
Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.
201645 citationsauthor #4
Abstract 2174: A high-throughput, high-content assay for the discovery of new inhibitors of DNA double-strand break repair
20161 citationsauthor #3
Abstract 2466: Development of a novel gene targeting and clone screening platform to engineer common pediatric glioma mutations into model cell lines
20160 citationsauthor #4
Abstract 4277: Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas
20160 citationsauthor #7
Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing.
201514 citationsauthor #10
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.
2015117 citationsauthor #6
PM-11DEVELOPMENT OF A NOVEL GENE TARGETING AND CLONE SCREENING PLATFORM TO ENGINEER COMMON PEDIATRIC GLIOMA MUTATIONS INTO MODEL CELL LINES
20150 citationsauthor #2
Identification and Characterization of Novel DNA Repair Inhibitors as Potential Tumor Cell Radiosensitizers
20150 citationsauthor #2
Patents on potential drugs to treat Alzheimer's disease: special emphasis on small peptides.
20141 citationsauthor #3
High-Throughput RNAi Screening Platform Identifies Novel Regulators of DNA Double-Strand Break Repair Pathways
20141 citationsauthor #3
Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
201436 citationsauthor #6
Alzheimers Disease – A Brief Overview
20140 citationsauthor #1
Identification of Gene Expression Signatures to Predict the Response of Low-Grade Lymphomas to Very Low Dose Radiation Therapy
20140 citationsauthor #3
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
2013169 citationsauthor #6
Development of a Novel Method to Create Double-Strand Break Repair Fingerprints Using Next-Generation Sequencing
20130 citationsauthor #6
High-Content, High-Throughput Screening for Novel Double-Strand Break Repair Inhibitors
20130 citationsauthor #2
Abstract 309: Induction of activation-induced cytidine deaminase (AID) by dendritic cells leads to genomic instability in human myeloma
20120 citationsauthor #4
Protein stains and applications.
20129 citationsauthor #1
Novel Detox Gel Depot Sequesters β-Amyloid Peptides in a Mouse Model of Alzheimer’s Disease
201216 citationsauthor #1
Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.
201250 citationsauthor #4
Novel Detox Gel Depot Sequesters β-Amyloid Peptides in a Mouse Model of Alzheimer’s Disease
20110 citationsauthor #1
Detoxification depot for beta-amyloid peptides.
20084 citationsauthor #1
Genetic transformation of a Corynebacterial symbiont from the Chagas disease vector Triatoma infestans.
200870 citationsauthor #2
Detoxification Depot for β -Amyloid Peptides
20089 citationsauthor #2
Expression of a functional single-chain antibody via Corynebacterium pseudodiphtheriticum
200812 citationsauthor #1
Prospects for paratransgenic applications to commercial mariculture using genetically engineered algae.
20063 citationsauthor #2
Neuronal localization and association of Niemann Pick C2 protein (HE1/NPC2) with the postsynaptic density.
200428 citationsauthor #2
Differential trafficking of the Niemann‐Pick C1 and 2 proteins highlights distinct roles in late endocytic lipid trafficking
200349 citationsauthor #6
Immunocytochemical localization of apolipoprotein D in oligodendrocyte precursor-like cells, perivascular cells, and pericytes in the human cerebral cortex
200129 citationsauthor #3
Role of Tissue Factor in Metastasis: Functions of the Cytoplasmic and Extracellular Domains of the Molecule
1999173 citationsauthor #2
Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications.
1996341 citationsauthor #1
SAMHD 1 promotes HR and DNA end resection independent of its dNTPase activity d SAMHD 1 complexes with CtIP and facilitates its recruitment to DNA damage sites Authors
year unknown0 citationsauthor #19
SAMHD 1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination Graphical
year unknown0 citationsauthor #19
CRISPR screening identifies novel PARP inhibitor classification based on 1 distinct base excision repair pathway dependencies
year unknown1 citationsauthor #4

TIMELINE

1996 341 citations

1999 173 citations

2001 29 citations

2003 49 citations

2004 28 citations

2006 3 citations

2008 95 citations

2011 0 citations

2012 75 citations

2013 169 citations

2014 38 citations

2015 131 citations

2016 46 citations

2017 669 citations

2018 276 citations

2019 127 citations

2020 3 citations

2021 98 citations

2022 151 citations

2023 6 citations

2024 14 citations

2025 3 citations

2026 0 citations

Unknown 1 citations

COAUTHOR MAP

CONCEPT FOOTPRINT